Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL‐1β with IL‐1β acting as a modulator of cellular differentiation
- 30 October 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 58 (1) , 82-94
- https://doi.org/10.1002/pros.10288
Abstract
BACKGROUND: Neutral endopeptidase (NEP) is a cell‐surface bound enzyme that cleaves and inactivates neuropeptides such as bombesin and substance P and is involved in the transition from hormonally regulated androgen‐dependent prostate cancer (PC) to androgen‐independent PC. Neuropeptides are implicated in growth regulation of different cell types and function as transmitters between the neuroendocrine and the immune system.METHODS: NEP‐expression, enzymatic activity of the membrane bound protein, cell proliferation, procalcitonin (PCT) production, and secretion as well as changes in cell morphology of prostatic cells were evaluated after treatment with the immunomodulatory cytokine interleukin‐1β (IL‐1β), neuropeptides (bombesin, substance P), and neuropeptide‐conditioned media derived from a human neuroendocrine cell line.RESULTS: Incubation of LNCaP tumor cells with IL‐1β resulted in a diminished proliferative activity, induction of neurite‐like outgrowth which was accompanied by the formation of tubular‐type mitochondria typical for neuronal/neuroendocrine cells, and an increased production and secretion of PCT. Conversely, proliferation of prostatic stromal cells was enhanced by the cytokine coming along with an increased number of Golgi‐apparatuses and ER‐cisternae. Bombesin had an antimitotic effect on LNCaP, but not on stromal cells. Substance P did not influence the growth of any of the cell types investigated, whereas neuropeptide‐conditioned media exerted a slightly mitogenic effect on both cell types. The activity of LNCaP cell‐surface bound NEP was enhanced by bombesin, but was diminished by substance P and neuropeptide‐conditioned media.CONCLUSIONS: Proliferation and activity of neuropeptide degrading NEP is regulated differently by immunomodulatory substances in PC cells and cells derived from the prostatic stroma with IL‐1β being a potent modulator of cellular differentiation and a potential target for anticancer drug design in PC cells.Keywords
Funding Information
- the Deutsche Forschungsgemeinschaft (AU 48/20-1)
This publication has 62 references indexed in Scilit:
- Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell linesClinical Science, 2002
- Expression, Localization and Activity of Neutral Endopeptidase in Cultured Cells of Benign Prostatic Hyperplasia and Prostate CancerJournal of Urology, 2002
- Identification and characterization of neutral endopeptidase (EC 3. 4. 24. 11) from human prostasomes-localization in prostatic tissue and cell linesThe Prostate, 2001
- Paraffin-Section Detection of CD10 in 505 Nonhematopoietic NeoplasmsAmerican Journal of Clinical Pathology, 2000
- Breast cancer cell-associated endopeptidase EC 24.11 modulates proliferative response to bombesinBritish Journal of Cancer, 1998
- Regulation of airway neurogenic inflammation by neutral endopeptidaseEuropean Respiratory Journal, 1998
- Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cellsCancer Letters, 1998
- Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer.International Journal of Molecular Medicine, 1998
- Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colonThe Esophagus, 1996
- Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.Proceedings of the National Academy of Sciences, 1988